Zymfentra (infliximab-dyyb subcutaneous injection – Celltrion) — Cigna

Initial criteria

• Patient is age ≥ 18 years
• According to the prescriber, the patient is currently receiving infliximab intravenous maintenance therapy or will receive induction dosing with an infliximab intravenous product within 3 months of initiating therapy with Zymfentra
• Medication is prescribed by or in consultation with a gastroenterologist

Reauthorization criteria

• Patient has been established on therapy for at least 6 months
• Patient meets at least one of the following (a or b): a) When assessed by at least one objective measure, patient experienced a beneficial clinical response from baseline (e.g., fecal or serum markers, endoscopy, and/or reduced dose of corticosteroids); OR b) Compared with baseline, patient experienced an improvement in at least one symptom (e.g., decreased pain, fatigue, stool frequency, and/or rectal bleeding)

Approval duration

initial: 6 months; renewal: 1 year